EA202092088A1 - Антитела анти-phf-тау и их применение - Google Patents

Антитела анти-phf-тау и их применение

Info

Publication number
EA202092088A1
EA202092088A1 EA202092088A EA202092088A EA202092088A1 EA 202092088 A1 EA202092088 A1 EA 202092088A1 EA 202092088 A EA202092088 A EA 202092088A EA 202092088 A EA202092088 A EA 202092088A EA 202092088 A1 EA202092088 A1 EA 202092088A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
phf
application
tau antibodies
tau protein
Prior art date
Application number
EA202092088A
Other languages
English (en)
Inventor
Кристоф Ван Колен
Марк Меркен
Линда Бароун
Эйлин Р. Лейси
Рупеш Нэнджунда
Джон Уилер
Цзиньцюань Ло
Марианн Боргерс
Original Assignee
Янссен Фармацевтика Нв
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Фармацевтика Нв filed Critical Янссен Фармацевтика Нв
Publication of EA202092088A1 publication Critical patent/EA202092088A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/563—Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Abstract

Описаны моноклональные антитела к тау-белку и их антигенсвязывающие фрагменты. Также описаны кодирующие антитела нуклеиновые кислоты, композиции, содержащие антитела, способы получения антител и применения антител для лечения или профилактики таких патологических состояний, как таупатия. Антитела изобретения также можно применять для количественного определения тау-белка в биологических пробах.
EA202092088A 2018-03-05 2019-03-04 Антитела анти-phf-тау и их применение EA202092088A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862638535P 2018-03-05 2018-03-05
PCT/IB2019/051748 WO2019171259A1 (en) 2018-03-05 2019-03-04 Anti-phf-tau antibodies and uses thereof

Publications (1)

Publication Number Publication Date
EA202092088A1 true EA202092088A1 (ru) 2020-11-13

Family

ID=67767358

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092088A EA202092088A1 (ru) 2018-03-05 2019-03-04 Антитела анти-phf-тау и их применение

Country Status (17)

Country Link
US (2) US10633435B2 (ru)
EP (1) EP3774888A4 (ru)
JP (2) JP7362636B2 (ru)
KR (1) KR20200130350A (ru)
CN (1) CN112105639A (ru)
AU (1) AU2019232631A1 (ru)
BR (1) BR112020018112A2 (ru)
CA (1) CA3093200A1 (ru)
EA (1) EA202092088A1 (ru)
IL (1) IL277075A (ru)
JO (1) JOP20200215A1 (ru)
MA (1) MA52235A (ru)
MX (1) MX2020009277A (ru)
PH (1) PH12020551373A1 (ru)
SG (1) SG11202008579UA (ru)
TW (1) TW201946654A (ru)
WO (1) WO2019171259A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3214310A1 (en) 2021-03-26 2022-09-29 Rupesh Nanjunda Anti-tau antibodies and uses thereof
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
TW202345899A (zh) * 2022-03-11 2023-12-01 比利時商健生藥品公司 多特異性抗體及其用途(三)
TW202346355A (zh) * 2022-03-11 2023-12-01 比利時商健生藥品公司 多特異性抗體及其用途(二)

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US7408027B1 (en) * 1991-12-06 2008-08-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften Tools for the diagnosis and treatment of Alzheimer's disease
EP0737208B1 (en) * 1993-12-21 2006-08-02 Innogenetics N.V. Monoclonal antibodies specific for phf-tau, hybridomas secreting them, antigen recognition by these antibodies and their applications
DE1250600T1 (de) * 2000-01-24 2003-03-06 Innogenetics Nv Diagnose von tauopathien durch bestimmung des verhältnisses von tau/phospho-tau
JP4619651B2 (ja) 2001-06-01 2011-01-26 コーネル・リサーチ・ファンデーション・インコーポレイテッド 前立腺特異的膜抗原に対する修飾抗体およびその使用
WO2004006955A1 (en) 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
US20050025763A1 (en) * 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
EP1697741A4 (en) 2003-12-04 2008-02-13 Xencor Inc PROCESS FOR PRODUCING PROTEIN VARIANTS WITH INCREASED HOST STRUCTURE CONTENT AND COMPOSITIONS THEREOF
DK2662390T3 (da) * 2004-06-21 2017-11-06 Squibb & Sons Llc Interferon alpha receptor 1-antistoffer og anvendelse heraf
EP1749839A1 (en) * 2005-07-22 2007-02-07 Novoplant GmbH Antigen binding polypeptides against F4(K88) fimbriae
WO2007064919A2 (en) * 2005-12-02 2007-06-07 Genentech, Inc. Binding polypeptides with restricted diversity sequences
WO2009085462A1 (en) 2007-12-19 2009-07-09 Centocor, Inc. Design and generation of human de novo pix phage display libraries via fusion to pix or pvii, vectors, antibodies and methods
US20100261620A1 (en) 2008-10-14 2010-10-14 Juan Carlos Almagro Methods of Humanizing and Affinity-Maturing Antibodies
WO2011047146A2 (en) 2009-10-14 2011-04-21 Centocor Ortho Biotech Inc. Methods of affinity maturing antibodies
EP2621950A4 (en) 2010-09-27 2015-09-02 Janssen Biotech Inc ANTIBODIES FOR BINDING HUMAN COLLAGEN II
SI2627672T1 (sl) * 2010-10-11 2018-10-30 Biogen International Neuroscience Gmbh Človeška protitelesa anti-tau
CN102457701B (zh) 2010-11-02 2014-03-12 华为终端有限公司 图像显示处理方法及装置
US20140017242A1 (en) 2010-12-03 2014-01-16 Diamedica Inc. Anti-bradykinin b2 receptor (bkb2r) monoclonal antibody
EP3135689B1 (en) * 2011-10-07 2018-12-19 AC Immune S.A. Phosphospecific antibodies recognising tau
MY186066A (en) * 2011-12-20 2021-06-18 Janssen Biotech Inc Anti-phf-tau antibodies and their uses
EP3486256A3 (en) * 2014-06-26 2019-08-28 Janssen Vaccines & Prevention B.V. Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
WO2016112078A2 (en) * 2015-01-08 2016-07-14 Janssen Biotech, Inc. Anti-phf-tau antibodies and their uses
TWI790642B (zh) 2015-06-05 2023-01-21 美商建南德克公司 抗-tau抗體及使用方法
WO2017181098A2 (en) * 2016-04-15 2017-10-19 Visterra, Inc. Antibody molecules to zika virus and uses thereof
TN2018000419A1 (en) * 2016-07-12 2020-06-15 H Lundbeck As Antibodies specific for hyperphosphorylated tau and methods of use thereof.
US11834494B2 (en) * 2016-07-26 2023-12-05 Washington University Antibodies to zika virus and methods of use thereof

Also Published As

Publication number Publication date
US10633435B2 (en) 2020-04-28
US20210002358A1 (en) 2021-01-07
AU2019232631A1 (en) 2020-09-24
MX2020009277A (es) 2021-01-08
TW201946654A (zh) 2019-12-16
US20190270793A1 (en) 2019-09-05
MA52235A (fr) 2021-02-17
JOP20200215A1 (ar) 2020-09-03
JP2024009870A (ja) 2024-01-23
WO2019171259A1 (en) 2019-09-12
IL277075A (en) 2020-10-29
JP7362636B2 (ja) 2023-10-17
PH12020551373A1 (en) 2021-08-16
EP3774888A4 (en) 2021-12-29
SG11202008579UA (en) 2020-10-29
BR112020018112A2 (pt) 2020-12-22
CN112105639A (zh) 2020-12-18
CA3093200A1 (en) 2019-09-12
EP3774888A1 (en) 2021-02-17
KR20200130350A (ko) 2020-11-18
JP2021515556A (ja) 2021-06-24

Similar Documents

Publication Publication Date Title
EA201992038A1 (ru) Анти-псф-тау-антитела и способы их применения
EA202092088A1 (ru) Антитела анти-phf-тау и их применение
EA201890302A1 (ru) Химерные рецепторы антигенов на основе однодоменных антител и способы их применения
EA202092825A1 (ru) Анти-sirpa антитела и способы их применения
EA201791961A1 (ru) Антитела, специфичные к cd47 и pd-l1
EA201792657A1 (ru) Связывающие lag-3 молекулы и способы их применения
EA201891992A1 (ru) Химерные рецепторы и способы их применения
EA201890655A1 (ru) Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул
EA202090247A1 (ru) Антитела против cd166 и их применения
EA201892616A1 (ru) Антитела к pd1 и lag3 для лечения злокачественного новообразования
EA201791666A1 (ru) Антитела к cd3, антитела к cd123 и биспецифические антитела, которые специфически связываются с cd3 и/или cd123
EA201791127A1 (ru) Антитела, содержащие модифицированные константные участки тяжелой цепи
EA202092735A1 (ru) Антагонизирующее cd73 антитело
EA202092907A1 (ru) Мультиспецифические связывающие белки и их усовершенствования
EA202092605A1 (ru) Антитела к ил-11ra
EA202191785A1 (ru) Антитела к ctla4 и способы их применения
EA201991546A1 (ru) Антигенсвязывающие белки против нейропилина и способы их применения
EA201890928A1 (ru) Антигенсвязывающие белки, которые активируют лептиновый рецептор
EA201992206A1 (ru) Моноклональное антитело к pd-l1
EA202091747A1 (ru) Составы антитела b7-h4
PE20211217A1 (es) Anticuerpos estabilizadores de trem2
EA202190807A1 (ru) Антитела к синуклеину
EA201791691A1 (ru) ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d
EA202192810A1 (ru) АНТИТЕЛА К PcrV, КОТОРЫЕ СВЯЗЫВАЮТ PcrV, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ АНТИТЕЛА К PcrV, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EA202191656A1 (ru) Анти-il-36 антитела и способы их применения